User login
Scientific advances and their translation from bench to bedside were front and foremost in the hematology-oncology sphere during 2015 and were bolstered by a record number of therapy approvals by the US Food and Drug Administration (FDA).1 The most recent of those approvals included elotuzumab and ixazomib (both with lenalidomide plus dexamethasone) for previously treated patients with multiple myeloma; and daratumumab as a single agent, also for previously treated multiple myeloma.
Click on the PDF icon at the top of this introduction to read the full article.
Scientific advances and their translation from bench to bedside were front and foremost in the hematology-oncology sphere during 2015 and were bolstered by a record number of therapy approvals by the US Food and Drug Administration (FDA).1 The most recent of those approvals included elotuzumab and ixazomib (both with lenalidomide plus dexamethasone) for previously treated patients with multiple myeloma; and daratumumab as a single agent, also for previously treated multiple myeloma.
Click on the PDF icon at the top of this introduction to read the full article.
Scientific advances and their translation from bench to bedside were front and foremost in the hematology-oncology sphere during 2015 and were bolstered by a record number of therapy approvals by the US Food and Drug Administration (FDA).1 The most recent of those approvals included elotuzumab and ixazomib (both with lenalidomide plus dexamethasone) for previously treated patients with multiple myeloma; and daratumumab as a single agent, also for previously treated multiple myeloma.
Click on the PDF icon at the top of this introduction to read the full article.